Previous studies have reported increased TLR2 expression in advanced ovarian cancer patients, and abnormal FADD expression has been noted in various solid tumors, including glioma, non-small cell lung cancer (NSCLC), and hepatocellular carcinoma (HCC) (43–46). This evidence concerns the gene FADD and central nervous system cancer.